Shattuck Labs (NASDAQ:STTK) Upgraded at Leerink Partnrs

Shattuck Labs (NASDAQ:STTK) was upgraded by investment analysts at Leerink Partnrs to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Separately, Leerink Partners assumed coverage on Shattuck Labs in a research report on Monday. They set an “outperform” rating and a $4.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Shattuck Labs presently has an average rating of “Moderate Buy” and an average price target of $7.50.

Shattuck Labs Price Performance

Shares of NASDAQ:STTK opened at $1.16 on Monday. The business’s 50 day simple moving average is $1.24 and its 200-day simple moving average is $1.60. The firm has a market capitalization of $55.38 million, a price-to-earnings ratio of -0.76 and a beta of 1.66. Shattuck Labs has a 12 month low of $0.94 and a 12 month high of $11.76.

Institutional Trading of Shattuck Labs

A number of institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in Shattuck Labs by 63.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock valued at $96,000 after buying an additional 10,667 shares during the last quarter. Geode Capital Management LLC boosted its position in Shattuck Labs by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock valued at $3,184,000 after buying an additional 8,133 shares during the last quarter. MetLife Investment Management LLC boosted its position in Shattuck Labs by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock valued at $86,000 after buying an additional 13,859 shares during the last quarter. State Street Corp boosted its position in Shattuck Labs by 7.8% in the 3rd quarter. State Street Corp now owns 766,410 shares of the company’s stock valued at $2,675,000 after buying an additional 55,579 shares during the last quarter. Finally, Barclays PLC boosted its position in Shattuck Labs by 299.5% in the 3rd quarter. Barclays PLC now owns 54,311 shares of the company’s stock valued at $189,000 after buying an additional 40,717 shares during the last quarter. 58.74% of the stock is owned by hedge funds and other institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.